Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE). (PubMed, J Crohns Colitis) - Oct 20, 2026 - P1b | "While PRV-300 demonstrated an acceptable safety profile, TLR3 blockade did not translate into clinical benefit despite exploratory evidence of target engagement. Our results are challenging a pivotal role of the mode-of-action for the pathogenesis of UC (funded by Provention Bio)."
Clinical • IO biomarker • Journal • P1 data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • TLR3
|
|
Camilla A Richmond; Francisco León; Gail M Comer; Jagoda Pokryszka; Walter Reinisch
|